Why BioMarin took gene therapy manufacturing into its own hands

As gene therapy companies fight for space at contract manufacturers, BioMarin has leveraged its expertise in biologics to design its own capabilities for manufacturing gene therapies and gain control of the process -- a move it thinks will set quality standards across the industry.

Demand for viral vectors continues to grow as more gene and CAR T cell therapies near the market, making the decision of whether to make or buy vectors a critical one. ...